- AU$11.43m
- AU$17.21m
- AU$7.47m
- 22
- 43
- 34
- 26
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.53 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -141.82% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 3.3 | 3.58 | 3.89 | 9.1 | 7.47 | n/a | n/a | 27.91% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Rhinomed Limited is an Australia-based wearable nasal technology company. The Company is engaged in the research, development and commercialization of consumer and medical devices. The Company’s products include Mute, Turbine, Rhinoswab Junior, and Rhinoswab. Mute technology is an easily inserted, comfortable and fully adjustable nasal stent or dilator. Turbine is designed to fit comfortably inside the nose and gently open each individual nostril to allow more airflow during sport, physical exertion, or focused breathing, such as yoga and meditation. Rhinoswab is a patented comfortable, self-administered nasal swab that provides high-yield sampling and fits existing pathology workflows.
Directors
- Ronald Dewhurst CHM
- Michael Johnson CEO
- Sean Slattery SEC
- John Ao NED
- Eric Knight NED
- Brent Scrimshaw NED
- Last Annual
- June 30th, 2023
- Last Interim
- June 30th, 2023
- Incorporated
- February 9th, 2004
- Public Since
- September 21st, 2007
- No. of Shareholders
- 1,441
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 285,719,694
- Address
- Level 1, 132 Gwynne St, Cremorne, RICHMOND, 3121
- Web
- https://www.rhinomed.global/
- Phone
- +61 384160900
- Auditors
- Grant Thornton Audit Pty Ltd
Upcoming Events for RNO
Full Year 2024 Rhinomed Ltd Earnings Release
Similar to RNO
4DMedical
Australian Stock Exchange - SEATS
Adherium
Australian Stock Exchange - SEATS
Allegra Medical Technologies
Australian Stock Exchange - SEATS
Ansell
Australian Stock Exchange - SEATS
Anteris Technologies
Australian Stock Exchange - SEATS
FAQ
What is the Rhinomed share price?
As of Today at 18:18 UTC, shares in Rhinomed are trading at AU$0.04. This share price information is delayed by 15 minutes.
How has the Rhinomed share price performed this year?
Shares in Rhinomed last closed at AU$0.04 and the price had moved by -56.52% over the past 365 days. In terms of relative price strength the Rhinomed share price has underperformed the ASX All Ordinaries Index by -57.51% over the past year.
What are the analyst and broker recommendations for Rhinomed?
The overall consensus recommendation for Rhinomed is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Rhinomed dividend yield?
Rhinomed does not currently pay a dividend.
Does Rhinomed pay a dividend?
Rhinomed does not currently pay a dividend.
When does Rhinomed next pay dividends?
Rhinomed does not currently pay a dividend.
How do I buy Rhinomed shares?
To buy shares in Rhinomed you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Rhinomed?
As of the previous close price of AU$0.04, shares in Rhinomed had a market capitalisation of AU$11.43m.
Where are Rhinomed shares listed?
Here are the trading details for Rhinomed:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: RNO
What kind of share is Rhinomed?
Based on an overall assessment of its quality, value and momentum Rhinomed is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Rhinomed share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Rhinomed share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rhinomed. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -49.25%.
As of the last closing price of AU$0.04, shares in Rhinomed were trading -38.74% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Rhinomed PE Ratio?
The Rhinomed PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.04.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Rhinomed?
Rhinomed's management team is headed by:
- Ronald Dewhurst - CHM
- Michael Johnson - CEO
- Sean Slattery - SEC
- John Ao - NED
- Eric Knight - NED
- Brent Scrimshaw - NED